Interactive Video Gaming Device Could Aid MS Patients
|
By LabMedica International staff writers Posted on 23 Aug 2016 |

Image: Using Kinect motion-capture camera may improve evaluation of gait pathology in multiple sclerosis patients by increasing objectivity in diagnosis and treatment monitoring (Photo courtesy of the Montreal Neurological Institute & Hospital and McGill University).
A commonly used 3D depth-sensing camera could become a low-cost means of monitoring treatment effectiveness for walking difficulties of patients with gait-impairing diseases such as multiple sclerosis (MS).
The Microsoft “Kinect” motion-detection camera can be hooked up to an Xbox gaming console or a Windows computer for interactive video activities such as tennis and dancing. A team of researchers led by McGill University (Montreal, Quebec, Canada) postdoctoral fellow Farnood Gholami, supervised by Prof. Jozsef Kövecses, collaborated with Daria Trojan, physiatrist at the Montreal Neurological Institute and Hospital, to test whether the Kinect could detect the differences in gait of MS patients compared to healthy individuals. The tool could be useful “to assess treatment effects of certain interventions such as rehabilitation or medication, and to document MS disease progression as reflected by gait deterioration. It may also be useful as a measure in clinical trials,” said Trojan. Additional collaboration was with Behnood Gholami at AreteX Systems Inc. (Hoboken, NJ, USA) and Wassim M. Haddad at Georgia Institute of Technology, (Atlanta, GA, USA).
In current clinical practice, the walking movement of MS patients is usually assessed by their doctors using subjective evaluations that may distort results such that different clinicians may give different evaluations for the same patient. Using computer algorithms that quantify patient walking patterns detected by a camera can reduce potential for human error.
Using Kinect, Dr. Gholami captured the movement of 10 MS patients and 10 members of an age-and-sex-matched control group. The MS patients had previously been assessed for gait abnormalities using the traditional clinician method. Using the data, the team then developed computer algorithms that quantified gait characteristics of MS patients and healthy people. They found that gait characteristics measured with the Kinect camera and analyzed with the developed algorithms were reproducible when assessed at one visit and were different between MS patients and the healthy individuals. Moreover, the gait characteristics of MS patients obtained by the algorithm were correlated with clinical measures of gait. In addition, the algorithms could mathematically define the characteristics of gait in MS patients at different severity levels, accurately determining the level of gait abnormality.
Dr. Gholami became interested in using motion-capture technology for clinical purposes as a PhD student, but the equipment he was using at the time was very expensive, difficult to use, and non-portable, making widespread clinical use prohibitive. Kinect is an inexpensive tool that appears to be accurate enough to do the job. “This tool may help the clinician provide a better diagnosis of gait pathology, and may be used to observe if a prescribed medication has been effective on the gait of the patient or not,” he said, “Our developed framework can likely be used for other diseases causing gait abnormalities as well, for instance Parkinson’s disease.” The next step is to conduct a study with a larger group of MS patients, including evaluation in a gait laboratory, using a newer version of the Kinect device to improve accuracy.
The study, by Gholami F et al, was published July 21, 2016, in the IEEE Journal of Biomedical and Health Informatics.
Related Links:
McGill University
The Microsoft “Kinect” motion-detection camera can be hooked up to an Xbox gaming console or a Windows computer for interactive video activities such as tennis and dancing. A team of researchers led by McGill University (Montreal, Quebec, Canada) postdoctoral fellow Farnood Gholami, supervised by Prof. Jozsef Kövecses, collaborated with Daria Trojan, physiatrist at the Montreal Neurological Institute and Hospital, to test whether the Kinect could detect the differences in gait of MS patients compared to healthy individuals. The tool could be useful “to assess treatment effects of certain interventions such as rehabilitation or medication, and to document MS disease progression as reflected by gait deterioration. It may also be useful as a measure in clinical trials,” said Trojan. Additional collaboration was with Behnood Gholami at AreteX Systems Inc. (Hoboken, NJ, USA) and Wassim M. Haddad at Georgia Institute of Technology, (Atlanta, GA, USA).
In current clinical practice, the walking movement of MS patients is usually assessed by their doctors using subjective evaluations that may distort results such that different clinicians may give different evaluations for the same patient. Using computer algorithms that quantify patient walking patterns detected by a camera can reduce potential for human error.
Using Kinect, Dr. Gholami captured the movement of 10 MS patients and 10 members of an age-and-sex-matched control group. The MS patients had previously been assessed for gait abnormalities using the traditional clinician method. Using the data, the team then developed computer algorithms that quantified gait characteristics of MS patients and healthy people. They found that gait characteristics measured with the Kinect camera and analyzed with the developed algorithms were reproducible when assessed at one visit and were different between MS patients and the healthy individuals. Moreover, the gait characteristics of MS patients obtained by the algorithm were correlated with clinical measures of gait. In addition, the algorithms could mathematically define the characteristics of gait in MS patients at different severity levels, accurately determining the level of gait abnormality.
Dr. Gholami became interested in using motion-capture technology for clinical purposes as a PhD student, but the equipment he was using at the time was very expensive, difficult to use, and non-portable, making widespread clinical use prohibitive. Kinect is an inexpensive tool that appears to be accurate enough to do the job. “This tool may help the clinician provide a better diagnosis of gait pathology, and may be used to observe if a prescribed medication has been effective on the gait of the patient or not,” he said, “Our developed framework can likely be used for other diseases causing gait abnormalities as well, for instance Parkinson’s disease.” The next step is to conduct a study with a larger group of MS patients, including evaluation in a gait laboratory, using a newer version of the Kinect device to improve accuracy.
The study, by Gholami F et al, was published July 21, 2016, in the IEEE Journal of Biomedical and Health Informatics.
Related Links:
McGill University
Latest Technology News
- Autonomous Robotic System Receives FDA Authorization for Blood Collection
- Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
Channels
Clinical Chemistry
view channel
Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease
Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. Confirmation typically relies on cerebrospinal... Read more
Blood Test Markers Could Help Identify Older Adults at Risk of Disability
Maintaining independence into very old age is a growing public health challenge as Japan’s population rapidly ages. Nearly 60% of Japanese adults aged 85 years and older already receive support through... Read moreMolecular Diagnostics
view channel
New Liquid Biopsy Approach Shows Promise for Detecting Breast Cancer Recurrence
Many liquid biopsy strategies for monitoring breast cancer recurrence focus on detecting genetic mutations in tumor DNA. Researchers are evaluating whether additional features of circulating cell-free... Read more
Whole-Blood RNA Test Could Improve Breast Cancer Screening in Dense Breasts
Breast cancer screening continues to face challenges, including limited detection of small tumors and uneven participation, particularly among women with dense breasts. These limitations can leave diagnostic... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
AI-Based Antibody Profiling Predicts Strength of COVID-19 Vaccine Response
Vaccine-induced protection can vary widely between individuals, creating uncertainty for clinicians, particularly in patients with immunosuppressive conditions. Demographic and health factors explain only... Read more
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read morePathology
view channel
AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more
New Review Highlights Intelligent Agents as Next Step for Digital Pathology
Digital pathology remains constrained by models that classify single images without mirroring how clinicians interrogate multiple slides, adjust magnification, and synthesize ancillary tests.... Read more
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read moreIndustry
view channel
New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies
HealthTab, a wholly owned subsidiary of Avricore Health, has entered a formal collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products in the UK through the... Read more







